All News

Bone density was found to be lower in those diagnosed with HIV vs those who were HIV-negative.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

Olivo Adriana, NP, highlights the importance of survivorship care and how providers are utilizing available tools to the best of their ability.

Adults with food insecurity report higher rates of long COVID and lower recovery, with Supplemental Nutrition Assistance Program (SNAP) participation and employment status affecting these associations.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

A new report from the National Alliance calls for data transparency and PBM reform to combat rising care costs, enhance equity, and improve well-being.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

Daily potato consumption may improve body composition and vascular health without worsening blood sugar in adults with type 2 diabetes.

DeepSeek-R1 was able to improve diagnosis management in these subspecialties while also lowering operation costs.

FDA intensifies efforts against misleading drug advertisements, aiming for transparency and accountability in pharmaceutical marketing practices.

Experts discuss innovative strategies to enhance dental care access in underserved Pennsylvania communities, emphasizing collaboration and cultural sensitivity in outreach efforts.

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

FDA expands selumetinib approval to younger children with NF1-related tumors.

Updated results from the MARIPOSA trial show that amivantamab plus lazertinib significantly reduces EGFR- and MET-driven resistance compared with osimertinib.

AD-related outcomes were compared in patients treated with JAK1 inhibitors and IL-13 antibodies, with short-term efficacy biomarkers considered for treatment outcomes.

A study explores how people with psoriasis use digital media, revealing benefits, pitfalls, and gaps in physician-patient communication.

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for patients who have multiple sclerosis.

Pulse of the Purchaser 2025 survey results showed the use of transparent PBMs more than doubled in just 1 year, from 12% to 31%.

Novel models incorporating tumor deposits outperform tumor TNM in predicting outcomes.

Despite overall growth in the radiology workforce, the proportion of pediatric radiologists specifically decreased from 2016 to 2023.

The FDA's removal of REMS for CAR T-cell therapies enhances access for community oncology, paving the way for innovative treatments and improved patient outcomes.

Bariatric surgery reduces the likelihood of obesity-related comorbidities compared with nonsurgical weight loss interventions.

Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.

Monthly SC amivantamab plus daily lazertinib demonstrated strong efficacy and tolerability in EGFR-mutated advanced NSCLC, providing a convenient alternative to IV dosing.

Extended hospital stays among Medicare Advantage beneficiaries translated to an estimated 1.8 million additional hospital bed days in 2022.

A study finds stronger CV protection from glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with higher BMI, with kidney benefits consistent across all groups.

Central nervous system (CNS) metastases in EGFR-mutant non–small cell lung cancer (NSCLC) remain a major challenge, with emerging therapies and evolving trial designs aiming to improve outcomes and address unmet needs.

Reducing the deferral period from 12 months to 3 months for those with high-risk behaviors did not increase the incidence of infectious diseases like HIV and hepatitis B appearing in donated blood.